On December 16, 2025, Aeovian Pharmaceuticals, a clinical-stage biopharmaceutical company developing highly selective small molecule therapeutics that restore cellular metabolic quality control, announced it has closed an oversubscribed $55 million Series B financing that will fund completion of a Phase 2 proof-of-concept study for its lead development candidate, AV078, in tuberous sclerosis complex (TSC)-related refractory epilepsy. Proceeds from the financing will support the advancement of AV078 into a Phase 2 proof-of-concept study in participants with TSC-refractory epilepsy. Wilson Sonsini Goodrich & Rosati advised Aeovian Pharmaceuticals on patent matters related to the transaction.

The funding round was co-led by new investors Luma Group and CTI Life Sciences Fund, with participation from Foresite Capital, SymBiosis, the TSC Alliance Endowment Fund, and Wilson Sonsini. Existing investors Apollo Health Ventures, Hevolution, Sofinnova Investments, and venBio also supported the financing.

The Wilson Sonsini team that advised Aeovian Pharmaceuticals on patent matters includes Julia Minitti, Jose Martinez, Trevor Lohrey, and Jane Yang.

For more information, please see Aeovian Pharmaceuticals’ news release.